Compras y ventas de empresas estadounidenses

[Bolseador]

@carlodago

A mi parece que se me ha escapado TXN

La tienes a menos 12% vs hace un mes…

[carlodago]

Sí, pero después de verla tocar los 140$, pillarlas a 160$ no es tan atractivo… el sesgo de anclaje es lo que tiene.
Ahora en serio, si no llevara unas cuantas ya, sí que compraría TXN al precio actual, pero al ir medianamente servido, soy más exigente en precio a la hora de ampliar.

[carlodago]

Hoy me ha entrado otra compra de PEP a 132,5$, así que sigo acumulando.

[Tiodelcazo]

Han caído unas ARE por aqui

[Seth]

Ayer fueron dos UNH a 410

[Crockett]

Ayer cayeron unas pocas Nike

[valdomero]

Ayer también amplié ARE

[Erro]

Yo aumente Google ayer

[PepeElmio]

Se está poniendo dudoso el panorama… mi analista me dice:

Alexandria Real Estate: AFFO Beat Over shadowed by Guidance Cut and Rising Debt Concerns

Alexandria Real Estate Equities (ARE) reported first-quarter 2025 results that beat expectations on Adjusted Funds From Operations (AFFO)[cite: 11], but this positive note was drowned out by significant concerns, leading to a sharp drop in the stock price[cite: 2, 9]. The overall tone for a retail investor leans heavily towards caution due to lowered future expectations and increasing financial pressures[cite: 21, 30, 34].

Why it matters:

• Guidance Slashed Despite Q1 Beat: Management lowered the full-year 2025 AFFO guidance by 7 cents per share, a significant reduction (~0.75%)[cite: 21, 23]. This signals slower re-leasing of vacant properties and issues leasing up new developments, directly impacting future profitability expectations[cite: 25].
• Occupancy Drop & Leasing Headwinds: Occupancy fell notably from 94.6% to 91.7% in Q1 2025[cite: 14], although this was somewhat anticipated[cite: 17, 19]. However, the slower-than-expected lease-up points to broader market challenges, like budget cuts hitting the life science sector ARE serves, potentially impacting demand[cite: 25, 44].
• Rising Debt Levels & Construction Halts: Debt-to-Adjusted EBITDA ratio climbed to 5.9x (quarter annualized), nearing a concerning 6x threshold[cite: 30, 33]. Furthermore, ARE plans to halt construction on some pipeline projects later in the year, which could leave capital stranded and signals financial strain[cite: 26, 28, 29].
• Challenging Asset Sales: While ARE is selling assets, a recent $124 million property sale required ARE to provide $91 million in seller financing at a high 12% interest rate[cite: 49, 51]. This suggests difficulty in selling assets at desired prices and could mean that Net Asset Value (NAV) estimates are overly optimistic[cite: 51, 52].

The bottom line:

• Weakened Investment Thesis: The lowered guidance, rising debt, occupancy pressures, and difficulties in asset sales significantly weaken the investment case for a retail investor, suggesting increased risk[cite: 6, 21, 30, 43, 51]. The analyst expresses doubt about the investment grade rating surviving long-term[cite: 7].
• Significant Headwinds: The company faces strong headwinds similar to the office REIT sector, driven by structural supply issues and evaporating demand due to budget cuts in the life sciences sector[cite: 43, 44]. While lab space isn’t directly impacted by “work from home,” the underlying demand drivers are weakening[cite: 44].

Outlook:

The near-term outlook appears challenging, with AFFO expected to contract after a long growth period, and analysts forecasting that 2026 and 2027 results could come in below 2025 levels[cite: 35, 36, 38]. While the stock is significantly oversold, suggesting a potential short-term bounce[cite: 39, 41], the underlying fundamentals present considerable risks[cite: 43]. For a retail investor, the key concerns are the declining occupancy trends[cite: 14, 45], high leverage potentially forcing asset sales in a difficult market[cite: 30, 47, 48, 51], and the overall health of the life science tenant base[cite: 44]. Caution is advised, as the path forward involves navigating significant financial and market headwinds[cite: 6, 43].

[911_9]

Incremento posición en SBUX en un 50% a 77,5$. Un -10% en apertura no se ve todos los días, el tiempo dirá si fue buen precio o no.

[valdomero]

Cuando la cosa pinta mal es cuando hay que comprar, no ? Eso dicen…

[Jose_A_Hernandez]

compra de ARE por debajo de 72 y cierro el chiringuito

[PepeElmio]

De acuerdo, pero la última vez cortó el dividendo.

Igual yo pienso q si hay aranceles se tendría que ver beneficiada xq deberían tener más demanda de espacio de alquiler.

El problema es si tiene que volcar en libros impairments x venta de activos como le está pasando ahora.

A ver… a 7% yield se pone jugosa.

[Gante]

Ahora me ha llegado el turno.

Inicio posición en LVMH y PepsiCo.

[Juanmanuel]

¡ Valiente !.. …Es probable que yo sea algo cobardica y necesite un margen mayor de seguridad.

Salu2

[Gante]

Llevo meses esperando, de valiente, nada xD

A todo esto, hoy he estado a punto de ampliar Nike. Hubieran sido las tres coincidiendo en PER 19

[Seth]

Hola
Ayer me entró una orden de UNH a 410
Con el cambio de divisa la compra se reduce todo bastante
Pero vamos, que si sigue en caída compraré de nuevo creo yo

[Lucio]

Amplio TROW a 89,37 $.

[Shallan]

UNH a 401,5

[Rubifen]

No has podido aguantar a los 400 ehh jajaja